Get it on Google Play

Omeros narsoplimab receives second negative EU opinion

October 16, 2026 6:20 AM EDT Send to a Friend
Omeros Corporation (Nasdaq: OMER) said the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) issued a negative ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login